Improving seasonal and pandemic influenza vaccines

Influenza and other Respiratory Viruses

Volumn 2, Issue 6, 2008, Pages 229-235

  Saville, Melanie ^a   Marsh, Grenville ^a   Hoffenbach, Agnes ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Adjuvants; Human; Immunologic; Influenza; Influenza vaccine; Intradermal injections

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; VIROSOME; VIRUS HEMAGGLUTININ;

AGE DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DEVICE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TREATMENT FAILURE; EMULSION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INJECTION SITE REACTION; LYMPH NODE; MORBIDITY; MORTALITY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; T LYMPHOCYTE; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; VIRUS STRAIN; ADULT; AGED; EPIDEMIC; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; UTILIZATION REVIEW;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; MIDDLE AGED; YOUNG ADULT;

EID: 58149345985     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2008.00060.x     Document Type: Review

References (55)

1. Tripp RA, Tompkins SM. Recombinant vaccines for influenza virus. Curr Opin Investig Drugs 2008;9:836-845.
2. de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007;26:119-127.
3. World Health Organization. Fifty-Sixth World Health Assembly. Prevention and Control of Influenza Pandemics and Annual Epidemics, (Agenda Item 14.14). Geneva: WHA56.19, 2003.
4. Elliot AJ, Fleming DM. Influenza and respiratory syncytial virus in the elderly. Expert Rev Vaccines 2008;7:249-258.
5. The Macroepidemiology of Influenza Vaccination (MIV) Study Group. The macro-epidemiology of influenza vaccination in 56 countries, 1997-2003. Vaccine 2005;23:5133-5143.
6. Arnoux S, Weinberger C, Gessner BD. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use. Vaccine 2007;25:7720-7731.
7. Jansen AG, Sanders EA, Nichol KL, van Loon AM, Hoes AW, Hak E. Decline in influenza-associated mortality among Dutch elderly following the introduction of a nationwide vaccination program. Vaccine 2008;26:5567-5574.
8. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-527.
9. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998;158:1769-1776.
10. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003;348:1322-1332.
11. Rivetti D, Jefferson T, Thomas R et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006;3:CD004876.
12. Simonsen L, Viboud C, Taylor R. Influenza vaccination in elderly people. Lancet 2005;366:2086.
13. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005;165:265-272.
14. Webster RG. Immunity to influenza in the elderly. Vaccine 2000;18:1686-1689.
15. Fiore AE, Shay DK, Broder K et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008;57:1-60.
16. Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008;46:1078-1084.
17. McElhaney JE. The unmet need in the elderly: Designing new influenza vaccines for older adults. Vaccine 2005;23(Suppl. 1):S10-S25.
18. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007;6:699-710.
19. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-2680.
20. de Bruijn IA, Nauta J, Cramer WC, Gerez L, Palache AM. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2005;23(Suppl 1):S39-S49.
21. Blank PR, Schwenkglenks M, Szucs TD. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 2008;8:272.
22. Delore V, Salamand C, Marsh G, Arnoux S, Pepin S, Saliou P. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip. Vaccine 2006;24:1586-1592.
23. El Sahly HM, Keitel WA. Clinical data on Fluarix: An inactivated split seasonal influenza vaccine. Expert Rev Vaccines 2008;7:713-719.
24. Lambert PH, Laurent PE. Intradermal vaccine delivery: Will new delivery systems transform vaccine administration? Vaccine 2008;26:3197-3208.
25. Micozkadioglu H, Zumrutdal A, Torun D, Sezer S, Ozdemir FN, Haberal M. Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Ren Fail 2007;29:285-288.
26. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: From immunology to clinical practice. Expert Rev Vaccines 2008;7:1201-1214.
27. Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007;25:8833-8842.
28. Laurent A, Mistretta F, Bottigioli D et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 2007;25:6423-6430.
29. Holland D, Booy R, Looze FD et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: A randomized controlled trial. J Infect Dis 2008;198:650-658.
30. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek M-P, Saville M. Intradermal influenza vaccine elicits superior immunogenicity in adults aged ≥60 years: A randomized controlled phase 3 trial. 13th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia, International Society for Infectious Diseases, 19-22 June 2008.
31. Centers for Disease Control and Prevention (CDC). State-specific influenza vaccination coverage among adults aged > or =18 years-United States, 2003-04 and 2005-06 influenza seasons. MMWR Morb Mortal Wkly Rep 2007;56:953-959.
32. De Lataillade C, Auvergne S, Rivas N, Delannoy I. 2005 and 2006 seasonal influenza vaccination coverage rates and drivers in ten countries from Africa, Asia Pacific, Europe, Latin America and the Middle East. J Public Health Policy 2008 (in press).
33. Orr P. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004-2005 season. Can Commun Dis Rep 2004;30:1-32.
34. Hofmann F, Ferracin C, Marsh G, Dumas R. Influenza vaccination of healthcare workers: A literature review of attitudes and beliefs. Infection 2006;34:142-147.
35. Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333-1340.
36. Langley JM, Faughnan ME. Prevention of influenza in the general population. CMAJ 2004;171:1213-1222.
37. Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, de Jong-van den Berg LT. Pharmacoeconomics of influenza vaccination for healthy working adults: Reviewing the available evidence. Drugs 2002;62:1013-1024.
38. Prosser LA, O'Brien MA, Molinari NA et al. Non-traditional settings for influenza vaccination of adults: Costs and cost effectiveness. Pharmacoeconomics 2008;26:163-178.
39. Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med 2008;121(7 Suppl. 2):S28-S35.
40. Leroux-Roels I, Vets E, Freese R et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008 (in press).
41. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008;358:261-273.
42. Li S, Liu C, Klimov A et al. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 1999;179:1132-1138.
43. Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: An H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005;23:2943-2952.
44. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-1351.
45. U.S. Food and Drug Administration. FDA Approves First U.S. Vaccine for Humans Against the Avian Influenza Virus H5N1. FDA News 2007. available at http://www.fda.gov/bbs/topics/NEWS/2007/NEW01611.html. accessed 29 September 2008.
46. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008;197:580-583.
47. Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006;367:1657-1664.
48. Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Pepin S, Nougarede N. Safety and immunogenicity of candidate pandemic influenza A/H5N1 vaccine in children. Third European Influenza Conference, Vilamoura, Portugal, European Scientific Working Group on Influenza, 14-17 September 2008.
49. El Sahly HM, Keitel WA. Pandemic H5N1 influenza vaccine development: An update. Expert Rev Vaccines 2008;7:241-247.
50. Bernstein DI, Edwards KM, Dekker CL et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008;197:667-675.
51. Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-1943.
52. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 2007;370:580-589.
53. Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: Protection against H5N1 challenge without disease enhancement. J Virol 2008;82:2565-2569.
54. Bigger J, Ruat C, Vasconcelos D, Legastelois I, Stark G, Caillet C. A new adjuvanted low-dose candidate pandemic influenza a(H5n1) vaccine protect ferrets against homologous clade 1 viral challenge and induces clade 2 cross-reactive antibodies. International Symposium on Avian Influenza: Integration from Control to Knowledge, Bangkok,Thailand, National Center for Genetic Engineering and Biotechnology, 23-25 January 2008.
55. Levie K, Leroux-Roels I, Hoppenbrouwers K et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008;198:642-649.